



## Gamida Cell to Present Corporate Highlights at the Jefferies Healthcare Conference

May 31, 2023

BOSTON--(BUSINESS WIRE)--May 31, 2023-- [Gamida Cell Ltd.](#) (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that Michele Korfin, Chief Operating and Chief Commercial Officer, will present corporate highlights at the upcoming Jefferies Healthcare Conference on June 8, 2023 at 9:30 a.m. ET.

Ms. Korfin's presentation will include an overview of the company's corporate strategy and commercial strategy for Omisirge®.

The webcast will be available on the "Investors & Media" section of Gamida Cell's website at [www.gamida-cell.com](http://www.gamida-cell.com), and will be available for at least 14 days following the event.

### About Gamida Cell

Gamida Cell is a cell therapy pioneer working to turn cells into powerful therapeutics. The company's proprietary nicotinamide (NAM) technology leverages the properties of NAM to enhance and expand cells, creating allogeneic cell therapy products and candidates that are potentially curative for patients with hematologic malignancies. These include Omisirge®, an FDA-approved nicotinamide modified allogeneic hematopoietic progenitor cell therapy, and GDA-201, an intrinsic NK cell therapy candidate being investigated for the treatment of hematologic malignancies. For additional information, please visit [www.gamida-cell.com](http://www.gamida-cell.com) or follow Gamida Cell on [LinkedIn](#), [Facebook](#), [Twitter](#) and [Instagram](#).

Omisirge® is a registered trademark of Gamida Cell Inc. © 2023 Gamida Cell Inc. All Rights Reserved.

### Forward-Looking Statements

This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including with respect to the potentially life-saving or curative therapeutic and commercial potential of Omisirge® (omidubicel-only), the company's plans for commercial or strategic partnerships to support the launch of Omisirge. Any statement describing Gamida Cell's goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to a number of risks, uncertainties and assumptions including those related to clinical, scientific, regulatory and technical developments and those inherent in the process of developing and commercializing product candidates that are safe and effective for use as human therapeutics. In light of these risks and uncertainties, and other risks and uncertainties that are described in the Risk Factors section and other sections of Gamida Cell's Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission (SEC) on May 15, 2023, and other filings that Gamida Cell makes with the SEC from time to time (which are available at [www.sec.gov](http://www.sec.gov)), the events and circumstances discussed in such forward-looking statements may not occur, and Gamida Cell's actual results could differ materially and adversely from those anticipated or implied thereby. Although Gamida Cell's forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Gamida Cell. As a result, you are cautioned not to rely on these forward-looking statements.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20230531005879/en/): <https://www.businesswire.com/news/home/20230531005879/en/>

### Investor and Media Contact:

Dan Boyle  
Orangefiery  
[media@orangefiery.com](mailto:media@orangefiery.com)  
1-818-209-1692

Source: Gamida Cell Ltd.